All In Biotech

Drug Trial Radar · NCT05254743

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 737 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

737

Planned (sponsor's estimate)

Start

Jul 22, 2022

Primary completion

Oct 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.

Conditions

  • Chronic Lymphocytic Leukemia
  • Leukemia, Lymphocytic
  • Leukemia, B-cell
  • Small Lymphocytic Lymphoma

Interventions

  • PirtobrutinibDrug

    Administered orally.

  • IbrutinibDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1Time frame: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest] (approximately 3 years and 5 months)
  2. Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2Time frame: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest (Approximately 2 years and 3 months)

Locations

143 sites in 23 countries. Site status is shown where the registry gives one.

  • Pacific Cancer Medical Center, Inc

    Anaheim, California · Recruiting

  • TOI Clinical Research

    Cerritos, California · Recruiting

  • Stanford School of Medicine-Cancer Clinical Trials Office

    Palo Alto, California · Recruiting

  • California Cancer Associates for Research and Excellence

    San Marcos, California · Active not recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • Cancer Specialists of North Florida -St Augustine

    Saint Augustine, Florida · Recruiting

  • Florida Cancer Specialists East

    West Palm Beach, Florida · Recruiting

  • Hematology Oncology Clinic

    Baton Rouge, Louisiana · Active not recruiting

  • Tulane Cancer Center Office of Clinical Research

    New Orleans, Louisiana · Active not recruiting

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland · Recruiting

  • St. Vincent Frontier Cancer Center

    Billings, Montana · Recruiting

  • Cancer Care Associates Of York

    York, Pennsylvania · Active not recruiting

  • Prisma Health Cancer Institute

    Greenville, South Carolina · Active not recruiting

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee · Recruiting

  • Kelsey Research Foundation

    Houston, Texas · Active not recruiting

  • Lumi Research

    Kingwood, Texas · Recruiting

  • Virginia Cancer Institute

    Richmond, Virginia · Recruiting

  • Medical Oncology Associates, PS

    Spokane, Washington · Recruiting

  • MultiCare Health System Institute for Research and Innovation

    Spokane, Washington · Active not recruiting

  • Alexander Fleming

    Ciudad Autónoma de Buenos Aire, Argentina · Recruiting

  • Hospital Privado De Comunidad

    Mar del Plata, Argentina · Active not recruiting

  • Clínica de Nefrología, Urología y Enfermedades Cardiovasculares

    Santa Fe, Argentina · Recruiting

  • One Clinical Research

    Nedlands, Australia · Active not recruiting

  • Western Health, Sunshine Hospital

    St Albans, Australia · Active not recruiting

  • The Perth Blood Institute

    West Perth, Australia · Recruiting

  • Hanusch Krankenhaus

    Vienna, Austria · Active not recruiting

  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • VITAZ

    Sint-Niklaas, Belgium · Recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, Brazil · Recruiting

  • Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP

    Botucatu, Brazil · Recruiting

  • Hemocentro Unicamp

    Campinas, Brazil · Recruiting

  • Hospital Uopeccan - Centro de Pesquisa Clinica

    Cascavel, Brazil · Recruiting

  • Centro Integrado de Oncologia de Curitiba

    Curitiba, Brazil · Active not recruiting

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

    Curitiba, Brazil · Recruiting

  • Instituto do Câncer - Hospital São Vicente de Paulo

    Passo Fundo, Brazil · Recruiting

  • Centro Gaucho Integrado - Mae de Deus Center

    Porto Alegre, Brazil · Recruiting

  • Hospital de Clínicas de Ribeirão Preto

    Ribeirão Preto, Brazil · Recruiting

  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

    Santo André, Brazil · Recruiting

  • Centro Integrado de Pesquisa Clinica

    São José do Rio Preto, Brazil · Recruiting

  • Hospital BP

    São Paulo, Brazil · Recruiting

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.